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Abstract
Purpose:  To  evaluate  using  phantom  study  the  average  glandular  dose  (AGD)  and  image  quality
in breast  tomosynthesis.
Materials  and  methods:  The  study  was  performed  with  a  full-ﬁeld  digital  mammography  system
(Mammomat  Inspiration®,  Siemens,  Erlangen,  Germany)  combined  with  tomosynthesis  equip-
ment (3D).  For  AGD  evaluation,  polymethyl  methacrylate  (PMMA)  plates  and  a  dosimeter  were
used to  directly  measure  the  absorbed  doses  in  2D  and  in  3D.  The  doses  were  then  compared  to
the doses  displayed  on  the  equipment  using  the  Mann—Whitney  test.  Three  phantoms,  accred-
ited for  2D  digital  mammography  (MTM  100,  ACR  RMI  156,  BR3D),  were  imaged  three  times  in  2D
then in  3D.  For  each  acquisition,  the  AGD  was  recorded.  For  image  quality  assessment,  scores,
deﬁned by  the  rate  of  visible  inserts,  obtained  for  each  acquisition  both  in  2D  and  in  3D,  and
for each  phantom,  were  compared  (Kruskall—Wallis  and  post-hoc  Dunn  tests).
Results:  There  was  no  signiﬁcant  difference  between  the  measured  and  displayed  AGD,  both  in
2D and  in  3D  imaging  (P  >  0.05).  With  identical  acquisition  parameters,  AGD  were  signiﬁcantly
greater in  3D  than  in  2D  P  <  0.01).  For  phantoms  MTM  100  and  ACR  RMI  156,  there  was  no
signiﬁcant  difference  between  the  rate  of  visible  inserts  in  2D  and  in  3D  (P  =  0.06  and  P  =  0.36,
respectively).  However  for  phantom  BR3D,  the  rate  was  signiﬁcantly  higher  in  3D  than  in  2D
(P <  0.0001).
Conclusion:  Doses  are  signiﬁcantly  greater  in  3D  than  in  2D.  With  tomosynthesis,  out  of  the
three phantoms  tested,  only  phantom  BR3D  showed  a  higher  rate  of  visible  inserts.© 2015  Éditions  franc¸aises  de  rad
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Figure 1. Polymethyl methacrylate (PMMA) plate.32  
By  comparison  with  screen-ﬁlm  radiography,  digital  mam-
ography  improves  breast  cancer  screening  [1—3], reduces
verage  glandular  dose  [2—5]  by  about  22%  [4]  and  makes
t  possible  to  add  tomosynthesis  in  routine  use  [6]. The
ombination  of  tomosynthesis  with  digital  mammography
ncreases  diagnostic  accuracy  [6—15]  and  reduces  recall
ates  by  30  to  40%  [8,9].  In  the  United  States,  tomosynthe-
is  was  approved  by  the  Food  and  Drug  Administration  in
011  [16].  However,  recent  articles  have  reported  that  the
GD  per  view  is  higher  in  tomosynthesis  mode  than  with
ammography  alone  [13,15,17].  Therefore,  reducing  the
ose  is  essential  to  validate  a  possible  use  of  tomosynthe-
is  in  screening  programs.  In  addition,  the  absorbed  dose  in
omosynthesis  should  be  assessed  simultaneously  with  image
uality,  like  is  currently  done  for  2D  mammography  breast
ancer  screening  programs.  In  France,  regulatory  quality
ontrol  testing  of  digital  mammography  screening  is  done
ith  phantoms  in  order  to  obtain  reproducible  testing,  and
hereby  a  long-term  follow-up  of  mammography  systems.  In
rance,  only  phantom  MTM  100  (Meditest,  France)  is  used
n  mammography  screening  programs,  but  tomosynthesis  is
ot  covered  [18].  To  the  best  of  our  knowledge,  there  is  not
ne  speciﬁc  phantom  for  tomosynthesis  acquisitions,  unlike
or  2D  mammography.  However,  several  phantoms  are  on  the
arket  and  could  be  adapted  to  assess  breast  tomosynthesis
econstructions.
The  goal  of  this  study  was  to  evaluate  the  average  glan-
ular  dose  (AGD)  and  the  quality  of  the  images  obtained  by
omosynthesis  using  the  phantoms  currently  available.
aterials and methods
omosynthesis
ll  the  images  were  acquired  with  the  Mammomat
nspiration® mammograph  (Siemens,  Erlangen,  Germany).
The  3D  tomosynthesis  acquisition  parameters  were  the
ollowing:  an  overall  angle  of  50◦,  with  the  X-ray  tube
otating  25◦ in  both  directions  from  the  target  by  2-degree
ncrements  to  obtain  26  projection  views.  A  reconstruction
lgorithm  (Equalizing  Filtered  Back  Projection)  was  applied
o  obtain  1-mm  slices.
valuation of AGD in 2D and 3D imaging on
olymethyl metacrylate (PMMA) plates
he  AGD  was  evaluated  in  2D  and  3D  imaging,  on  PMMA
lates  of  varying  thickness.  Five  images  were  acquired  in
D  then  in  3D  with  PMMA  placed  on  the  detector  plate  while
he  thickness  varied  from  20  to  60  mm,  by  10-mm  increments
Fig.  1).  The  values  of  kV,  mAs  and  AGD  displayed  by  the
ammography  system  were  recorded.
Using  a  Piranha  dosimeter  (RTI  electronics  AB,  Sweden),
he  AGD  was  measured  for  2D  (noted  AGD)  and  for  3D  (noted
GDT).  The  AGD  was  calculated  based  on  the  entrance  sur-
ace  air  kerma  (ESAK).  Acquisitions  were  obtained  in  manual
ode,  with  parameters  selected  so  as  to  be  as  close  as  pos-
ible  to  those  used  in  clinical  practice.  The  detector  was
laced  on  the  compression  paddle  so  as  not  to  affect  the
GD  delivered  during  exposure  (Fig.  2).
Figure 2. Piranha (RTI electronics AB Sweden) dosimeter pos-
itioned on a PMMA plate ﬁxed by the compressor.
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Figure 3. Phantom MTM 100 (a), in 2D imaging (b) and in 3D tomosynthesis (c). The inclusions embedded in this phantom are: 7 groups of
microcalciﬁcations measuring (in mm): 0.250—0.300; 0.212—0.250; 0.180—0.212; 0.150—0.180; 0.125—0.150; 0.106—0.125; 0.090—0.106.
Seven groups of hemispheric elements equivalent to tumor masses with 75% glandular and 25% adipose tissue. Diameters are 3.17, 2.78,
2.38, 1.98, 1.59, 1.19, and 0.90 mm. Seven groups of three nylon ﬁbres imbedded in a wax matrix equivalent to ﬁbers simulating geometric
distortions. Diameters are 1.25 mm, 1 mm, 0.83 mm,  0.71 mm, 0.53 mm, 0.40 mm and 0.30 mm, respectively. 3D Imaging of the phantom
provides better visualization of the 3 groups of microcalciﬁcations [Arrow heads (c), 4 masses (arrow c) and 5 ﬁbres].
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b2D measurement of AGD
The  AGD  in  2D  imaging  is  obtained  by  formula  (1):
AGD  =  ESAK  ×  g  ×  c  ×  s  (1)
with  g  the  conversion  factor  to  calculate  the  AGD  based  on
the  ESAK  for  a  medium  dense  breast  (50%  glandularity);  with
c  the  correction  factor  for  the  density  of  the  breast;  and  with
s  the  correction  factor  for  the  X-ray  spectrum  (anode/ﬁlter
combination).
g  and  c  values  are  obtained,  if  necessary  by  linear  inter-
polation,  from  values  calculated  by  Dance  et  al.  [19—21].
3D measurement of AGD
AGD  was  measured  in  tomosynthesis  imaging  (noted  AGDT),
also  with  a  Piranha  detector.  Like  for  2D,  the  value  was  also
calculated  based  on  the  ESAK  and  noted  ESAKT,  but  with
3D  acquisition  parameters  dependent  on  the  corresponding
PMMA  thickness.  To  estimate  the  AGDT obtained  in  tomosyn-
thesis,  we  used  the  tables  of  Dance  et  al.  [22].  Because  of
the  angular  dependence  of  the  detector,  the  AGDT could  only
be  measured  in  ﬁxed  mode  with  the  detector  placed  on  the
compression  paddle  during  exposure,  when  the  incidence
of  the  X-ray  tube  was  ﬁxed  at  0◦ position.  The  X-ray  tube
remained  stationary.  The  Piranha  detector  was  not  moved
between  exposures.  Let  T  be  the  correction  factor  of  the
X-ray  tube  incidence  during  exposure.  This  T  value  is  based
T
i
in  the  thickness  of  the  breast  phantom  and  the  tables  of
ance  et  al.  [22]. The  AGDT for  the  tomosynthesis,  based  on
ormula  (1), was  obtained  by  formula  (2):
GDT =  ESAKT ×  g  ×  c  ×  s  ×  T  (2)
reast equivalent phantoms
he  following  three  phantoms  were  used:
phantom  MTM  100  (Meditest,  France)  (Fig.  3).  This  phan-
tom  has  characteristics  that  meet  the  requirements  of  the
French  regulatory  authorities  (Agence  Nationale  de  Sécu-
rité  du  Médicament  et  des  produits  de  santé,  ANSM)  and
is  mandatory  in  France  for  quality  control  testing  [1];
phantom  BR3D  (Meditest,  France)  (Fig.  4).  This  phantom
has  not  been  approved  for  the  French  regulatory  qual-
ity  control  testing,  but  was  designed  for  quality  control
testing  in  tomosynthesis  and  CT  scan;
phantom  ACR  RMI  156  (Siemens,  Erlangen,  Germany)
(Fig.  5).  This  phantom  is  used  in  the  United  States  and
is  accredited  by  the  American  College  of  Radiology  for
quality  controls  in  2D  mammography.
valuation of AGD in 2D and 3D imaging on
reast phantomshe  three  phantoms,  MTM  100,  BR3D  and  ACR  RMI  156,  were
maged  in  2D  and  in  3D.  In  addition,  phantom  BR3D  was
maged  over  a  thickness  range  of  1  to  6  slices;  the  slice
934  E.  Meyblum  et  al.
Figure 4. Phantom BR3D (a): the six slices of this phantom consist of a material equivalent to 50% glandular and 50% adipose tissue
to represent the mammary gland, but each slice has a different tissue distribution. Only one slice contains the combination of micro-
calciﬁcations, tumor masses and ﬁbres, as follows: 6 microcalciﬁcations measuring 0.130 mm, 0.165 mm, 0.196 mm, 0.230 mm,  0.275 mm
and 0.4 mm, respectively. Six spheroid masses equivalent to tumor masses with 75% glandular and 25% adipose tissue, measuring 1.80 mm,
2.38 mm, 3.18 mm, 3.96 mm, 4.76 mm, and 6.32 mm, respectively. Seven ﬁber-equivalents simulating geometric distortions. Diameters were
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s.30 mm, 0.53 mm, 0.71 mm, 0.83 mm, and 1.25 mm. In 2D imagin
roups of microcalciﬁcations (curved arrow) and at least 3 ﬁbres (a
ontaining  the  inserts  was  successively  placed  from  top  to
ottom.  For  each  phantom,  two  types  of  acquisition  modes,
pdose  and  AEC  (Automatic  Exposure  Control),  were  used,
n  2D,  then  in  3D  imaging.  The  Opdose  mode  works  automat-
cally  with  the  compression  system;  it  selects  the  acquisition
arameters  according  to  the  progressive  compression  resis-
ance  and  to  the  thickness  of  the  imaged  target.  The
EC  mode  is  semi-automatic  and  has  3  settings:  low  dose
—20%),  normal  dose  and  high  dose  (+20%).  Thus,  altogether,
r
p
v
igure 5. Phantom ACR RMI 156 (a). Phantom ACR RMI 156 consists o
nd 50% adipose tissue. It contains 6 groups of ﬁbers, 5 groups of micro
icrocalciﬁcations (curved arrow), 4 rounded masses (arrow head), 4 ﬁb
ame way, still with 2 groups of microcalciﬁcations (curved arrow), 4 rouly 3 masses are visible (arrow b), while 6 masses (arrow head), 4
 are visible in 3D imaging (c).
our  acquisition  modes  were  used:  Opdose,  low  dose  AEC,
ormal  dose  AEC  and  high  dose  AEC.  Table  1  shows  the  dif-
erent  acquisition  parameters.
Displayed  doses  were  recorded  for  each  phantom  and
ach  acquisition  mode,  after  both  2D  and  3D  imag-
ng.  The  doses  for  each  acquisition  parameter  were  only
ecorded  once,  because  the  reproducibility  of  the  dis-
layed  doses  and  the  X-ray  tube  had  been  previously
eriﬁed  by  the  medical  physicist  (unpublished  personal
f a material equivalent to the mammary gland with 50% glandular
calciﬁcations and 5 masses. In 2D imaging (b), at least 2 groups of
res (arrow) are visible. In 3D imaging (c), inserts are visible in the
nded masses (arrow head), 4 ﬁbres (arrow).
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Table  1  Acquisition  parameters  of  2D  and  3D  imaging  of  phantoms  MTM100,  ACR  RMI  156  and  BR3D  (S  =  slices).  The
compression  force  is  90  Newton.
Phantom  Acquisition  mode  2D  3D
kV  mAs  kV  mAs
MTM  100 Opdose  28  77.5 28 157
MTM  100  Low  dose  AEC  28  62.6  28  121.5
MTM  100  Normal  dose  AEC  28  76.5  28  156
MTM  100  High  dose  AEC  28  91.4  28  195
ACR  RMI  156  Opdose  28  78.3  28  150
ACR  RMI  156  Low  dose  AEC  28  70  28  114
ACR  RMI  156  Normal  dose  AEC  28  77.5  28  149
ACR  RMI  156 High  dose  AEC  28  92.3  28  185
BR3D  6 S  Opdose  30  147.5  30  389
BR3D  6 S  Low  dose  AEC  28  169  28  362
BR3D  6 S  Normal  dose  AEC  28  213.1  28  416.8
BR3D  6 S  High  dose  AEC  28  254.7  28  512.3
BR3D  5 S  Opdose  29  105  29  210.8
BR3D  5 S Low  dose  AEC  28  99  28  201.8
BR3D  5 S  Normal  dose  AEC  28  122.3  28  242.5
BR3D  5 S High  dose  AEC  28  145.2  28  305.8
BR3D  4 S Opdose  28  71  28  149
BR3D  4 S Low  dose  AEC  28  58.3  28  114
BR3D  4 S Normal  dose  AEC 28  71.3  28  148.3
BR3D  4 S High  dose  AEC 28  84.8  28  183
BR3D  3 S Opdose  27  48.5  27  104.8
BR3D  3 S Low  dose  AEC 28  35  28  69.3
BR3D  3 S Normal  dose  AEC 28  42.5 28 90.8
BR3D  3 S High  dose  AEC 28  50  28  112.3
BR3D  2 S Opdose  26  33  26  71.8
BR3D  2 S  Low  dose  AEC  28  21.4  28  55
BR3D  2 S  Normal  dose  AEC  28  25.6  28  55
BR3D  2 S  High  dose  AEC  28  29.7  28  67.5
BR3D  1 S  Opdose  24  20.8  24  59.3
BR3D  1 S  Low  dose  AEC  28  13.9  X  X
BR3D  1 S  Normal  dose  AEC  28  16.1  X  X
BR3D  1 S  High  dose  AEC  28  18.3  28  55
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tdata)  through  ﬁve  successive  measures  on  PMMA  plates
in  2D.
Quality control testing of 2D and 3D imaging
on breast phantoms
For  the  quality  control  testing,  acquisitions  were  obtained
only  in  AEC  mode  (normal,  low  and  high  dose).  The  deci-
sion  to  select  only  the  AEC  mode  was  twofold:  ﬁrst,  the
doses  delivered  in  Opdose  and  normal  dose  AEC  are  iden-
tical  —  except  when  the  thickness  of  the  phantom  is  less  or
equal  to  1  cm,  and  secondly  because  the  AEC  mode  is  the
only  mode  that  provides  3  settings.
For  the  quality  control,  all  the  acquisitions  in  2D,  and
then  in  3D  mode,  were  repeated  3  times,  i.e.  6  series  of
acquisitions  for  each  phantom.  For  phantom  BR3D,  6  series
of  acquisitions  were  performed  for  each  position  of  the  slice
containing  the  inserts,  with  each  time  a  different  phantom
thickness  (1  to  6  slices).  3D  imaging  of  phantom  BR3D,  with
only  one  slice,  was  technically  impossible  in  normal  and
a
p
p
tow  dose  mode.  Altogether,  136  series  of  image  acquisitions
n  breast  phantom  were  obtained,  and  this,  for  each  AEC
etting,  normal  dose,  low  dose  and  high  dose.
ssessment of image quality in 2D and 3D
maging on breast phantoms
mages  were  read  on  a  21-inch-HD  screen  (5  million  pixels,
yngo  Mammo  Report,  Siemens,  Erlangen,  Germany)  by  two
enior  radiologists  specialized  in  senology  (THD  and  EM)  and
ne  junior  reader  (IF).  Readings  were  independently  per-
ormed,  at  different  times  of  the  day,  images  were  shown
n  a  random  order  and  results  represent  the  mean  scores
f  each  reader.  None  of  the  readers  had  been  speciﬁcally
rained.  Each  reader  counted  the  number  of  masses,  ﬁbers
nd  clusters  of  microcalciﬁcations  on  each  view  and  com-
ared  the  visible  inserts  to  the  total  number  of  inserts.  A
artially  visible  insert  was  scored  0.5.  Since  the  three  phan-
oms  contained  a  different  number  of  inserts,  results  were
936  E.  Meyblum  et  al.
Table  2  Comparison  between  measured  and  displayed  AGD  in  Opdose  mode,  with  varying  thickness  of  PMMA  plates.
The  measured  AGD  was  signiﬁcantly  higher  than  the  displayed  AGD,  but  with  a  difference  smaller  than  20.91%.  For  all
acquisitions,  AGD  in  3D  were  1.76  to  2.16  times  higher  than  in  2D.
PMMA  Plate
thickness
(mm)
2D  3D  Ratiob
AGD
measured
(mGy)
AGD
displayed
(mGy)
Relative
differencea
AGD
measured
(mGy)
AGD
displayed
(mGy)
Relative
differencea
20  0.63 0.55 —12.41 1.36 1.13 —17.01  2.16
30  0.85 0.76 —10.59 1.64 1.43 —12.72 1.93
40  1.10  0.87  —20.91  2.17  1.91  —11.98  1.97
50  1.61  1.51  —6.21  2.83  2.64  —6.78  1.76
60  1.98  1.81  —8.59  3.89  3.48  —10.57  1.96
a Between measured and displayed AGD (%).
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DBetween 3D- and 2D-measured AGD.
xpressed  as  a  rate,  the  number  of  visible  inserts  over  the
otal  number  of  inserts.
tatistics
he  displayed  AGD  were  compared  to  the  calculated  AGD
ased  on  the  ESKA  (Mann—Whitney  test).  For  each  phan-
om,  doses  were  compared  between  the  2D  and  3D  imaging
Mann—Whitney  test)  in  the  Opdose,  low  dose,  normal
ose  and  high  dose  AEC  modes.  For  each  phantom,  the
ates  of  visible  inserts  were  compared  between  2D  and  3D
T
P
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Table  3  AGD  in  mGy  and  ratio  between  AGD  in  3D  and  in  
altogether  4  different  modes:  Opdose  (fully  automatic),  and  A
settings:  low  dose  (20%  less  than  the  normal  dose),  normal  dose
each  acquisition.  The  DRL  for  the  2D  acquisitions  is  1.8  mGy.
PHANTOM  AGD  (mGy)  in  2D  
OPDOSE  AEC  
Low  dose  Normal  dose  High  
MTM  100  0.96  0.77  0.94  1.13  
ACR  RMI  156  0.98  0.88  0.97  1.15  
BR3D  6  slices  1.71  1.59  2.00  2.39  
BR3D  5  slices  1.27  1.07  1.32  1.57  
BR3D  4  slices  0.92  0.75  0.92  1.09  
BR3D  3  slices  0.68  0.55  0.67  0.79  
BR3D  2  slices 0.53 0.43  0.51  0.59  
BR3D  1  slice  0.70  0.34  0.39  0.44  Mann—Whitney  test).  Statistics  were  performed  on  Prism
oftware  (Graphpad  La  Jolla,  CA,  USA).
esults
osimetryable  2  shows  the  AGD  values  measured  in  2D  and  in  3D  with
MMA  plates.  Measured  and  displayed  values  of  AGD  were
ot  signiﬁcantly  different,  both  in  2D  and  in  3D  (P  >  0.05).
he  displayed  AGD  systematically  underestimated  the  dose
2D  for  each  breast  phantom.  2D  and  3D  acquisitions,  in
EC  (Automatic  Exposure  Control,  semi-automatic)  with  3
 and  high  dose  (20%  more).  The  doses  are  displayed  after
AGD  (mGy)  in  3D  (Ratio  AGD  3D/AGD  2D)
OPDOSE  AEC
dose  Low
dose
Normal
dose
High
dose
1.87
(1.94)
1.43
(1.85)
1.87
(1.98)
2.34
(2.07)
1.84
(1.87)
1.36
(1.54)
1.81
(1.87)
2.25
(1.9)  6
4.41
(2.58)
3.35
(2.11)
3.87
(1.93)
4.77
(1.99)
2.48
(1.95)
2.13
(1.99)
2.57
(1.95)
3.26
(2.08)
1.85
(2.01)
1.41
(1.88)
1.84
(2.00)
2.29
(2.10)
1.41
(2.07)
1.01
(1.83)
1.35
(2.01)
1.69
(2.14)
1.07
(2.01)
1.00
(2.32)
1.00
(1.95)
1.25
(2.12)
0.78
(1.11)
N/A  N/A  1.21
(2.75)
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Figure 6. Image quality is determined by the rate of visible inserts for the 3 phantoms, MTM 100 (a), ACR RMI 156 (b) and BR3D with 1
insert (c) and with 6 inserts (d), in 2D and 3D Imaging, in low dose, normal dose and high dose Automatic Exposure Control. The scores were
calculated as the number of visible inserts over the total number of inserts contained in the phantoms. This was repeated for the three
types of inserts: microcalciﬁcations, ﬁbers and masses. Phantom BR3D showed a better rate of visible inserts in 3D imaging than the other
ow: 3
i
r
e
w
(
i
cations.
Table  4  Rate  of  visible  inserts  (mean  ±  standard  devia-
tion)  for  the  different  slices  of  phantom  BR3D.
2D  3D  Relative  difference
3D/2D  (%)
1  Slice  0.9  1.0  11.1
2  Slices  0.6  0.9  50
3  Slices  0.5  0.8  60phantoms. 2D low: low dose AEC; 2D Normal: normal dose AEC; 3D L
dose AEC.
by  6.2  to  20.9%.  The  doses  obtained  in  2D  and  in  3D  on  breast
phantoms,  for  each  acquisition  mode  (Opdose,  low,  normal
and  high  dose)  are  shown  in  Table  3.  In  identical  acquisi-
tion  mode,  the  displayed  AGD  in  3D  were  signiﬁcantly  higher
than  all  the  AGD  obtained  in  2D  (P  <  0.01).  The  displayed
AGD  obtained  in  3D  was  1.75  to  2.15  times  higher  than  in
2D  on  PMMA  plate  and  1.5  (low  dose  AEC  phantom  ACR  RMI
156)  to  2.75  times  higher  (high  dose  AEC  mode,  phantom
BR3D  1  slice)  than  in  2D  (Tables  2  and  3),  with  equivalent
mode.
Comparison between quality scores based on
delivered dose
For  each  phantom,  no  signiﬁcant  difference  was  observed
between  the  scores  obtained  in  low  dose,  normal  dose  and
high  dose  AEC  mode  (P  =  0.58).
Comparison between quality scores in 2D and
3D for each phantom
For  phantoms  MTM  100  and  ACR  RMI  156,  no  signiﬁcant  dif-
ference  was  observed  between  the  rates  of  visible  insertsD low dose AEC; 3D Normal: 3D normal dose AEC; 3D High: 3D high
n  2D  and  in  3D  at  equivalent  dose  (P  = 0.06  and  P =  0.36,
espectively)  (Fig.  6).  However,  with  phantom  BR3D,  what-
ver  the  thickness  and  the  location  of  the  inserts,  the  rate
as  signiﬁcantly  higher  in  3D  than  in  2D  imaging  (P  <  0.0001)
Table  4) (Fig.  6).  The  increase  in  the  rate  of  visible  inserts
n  3D  was  higher  for  masses  and  ﬁbres  than  for  microcalciﬁ-4  Slices  0.5  0.8  60
5  Slices  0.4  0.8  100
6  Slices  0.4  0.8  100
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iscussion
he  results  obtained  in  this  study  conﬁrm  that  the  dose  lev-
ls  delivered  with  tomosynthesis  are  about  twice  those  of
D.  Average  doses  in  2D  ranged  between  0.8  and  1.14PmGy,
hich  is  below  the  diagnostic  reference  level  (DRL)  of
.8  mGy  [23]  for  high-ﬁeld  digital  mammography.  In  3D  imag-
ng,  there  is  no  DRL.  If  we  compare  the  delivered  dose  in
D  to  the  2D  DRL,  it  only  exceeds  by  10%  the  2D  reference
evel.
Moreover,  the  results  conﬁrm  that  the  displayed  dose
fter  each  acquisition  correlates  with  the  measured  dose,
ith  a  non-signiﬁcant  discrepancy,  lower  than  the  speciﬁ-
ations  of  the  manufacturer  (30%  discrepancy).  It  should
owever  be  noted  that  the  displayed  doses  systematically
nderestimated  the  measured  doses.
Routine  use  of  tomosynthesis  is  recent,  and,  to  the  best
f  our  knowledge,  only  few  studies  have  analyzed  the  doses
bsorbed  in  tomosynthesis  in  comparison  to  2D  mammogra-
hy.  On  the  other  hand,  the  existing  studies  have  shown  very
ariable  results  with  additional  doses  delivered  in  tomosyn-
hesis  from  +8%  to  +2.24  times  the  dose  delivered  in  2D
13,15,17].  In  our  study,  the  parameters  analyzed  are  those
sed  in  clinical  setting.  This  study  differentiates  the  scores
btained  in  the  3  different  AEC  acquisition  modes,  and  does
ot  show  a  signiﬁcant  difference  in  the  quality  scores  on
hantoms  for  the  three  modes.  This  suggests  that  the  low
ose  should  be  preferred.
Image  quality  analysis  of  tomosynthesis  conﬁrms  that
D  imaging  signiﬁcantly  improves  the  detection  of  abnor-
alities  [13—15].  For  phantom  BR3D,  the  improved  scores
btained  in  3D  compared  to  2D  are  similar  to  those  reported
n  the  literature  [14,15].  On  the  other  hand,  the  score  differ-
nces  for  phantoms  MTM  100  and  ACR  RMI  156  are  low,  which
as  to  be  expected  since  both  phantoms  were  developed  for
D  mammography  quality  control.
The  main  limitation  of  the  different  and  numerous  breast
hantoms  used  in  studies  is  their  uniformity.  The  mam-
ary  gland  is  difﬁcult  to  reproduce:  it  is  complex  and
he  proportion  of  the  elements  contained  in  it  is  variable
24—29].  However,  the  improvement  of  abnormality  detec-
ion  in  3D  imaging  varies  with  the  proportions  of  glandular
nd  adipose  tissue.  Phantom  BR3D  used  in  this  study  was
maged  with  different  theoretical  breast  thickness,  by  vary-
ng  the  number  of  slices  used,  and  with  different  positions
f  the  slice  containing  the  inserts.  In  our  study  on  phan-
om  in  3D  imaging,  the  detection  of  microcalciﬁcations  was
ot  as  clearly  improved  as  for  masses  and  ﬁbers.  This  is
n  agreement  with  the  ﬁndings  reported  in  the  literature
8—10,12,14].  Detection  of  microcalciﬁcations  is  essential
ince  intraductal  carcinoma  (CIC)  detected  only  through
icrocalciﬁcations  represent  19%  of  the  cancers  screened
30,31].  But  3D  allows  radiologists  to  use  methods,  such  as
he  maximum  intensity  projection  (MIP),  speciﬁc  to  multi-
lice  imaging,  to  detect  and  analyze  ﬁne  structures,  such  as
icrocalciﬁcations  [8,32].  This  has  not  been  assessed  in  our
tudy.
Also,  we  did  not  compare  3D  and  2D  scores  for  tomosyn-hesis  in  Combo  mode.  This  mode,  a  combined  3D—2D
ode  is  provided  by  the  manufacturer  of  the  mammogra-
hy  system.  This  mode  delivers  a  lower  dose  than  when  3D
omosynthesis  is  added  to  a  2D  acquisition.  The  reason  for
[E.  Meyblum  et  al.
his  absence  is  because  we  aimed  at  strictly  comparing  2D
nd  3D  acquisitions.
Other  methods  to  lower  doses  have  been  described  and
ave  not  been  assessed  here,  such  as  tomosynthesis  only,  the
ddition  of  only  one  incidence  in  tomosynthesis  [9,33],  or
 synthetic  2D  image  reconstruction  from  a  3D  acquisition,
hich  seems  promising  in  terms  of  abnormality  detection
34,35].
In conclusion,  our  results  on  phantoms  conﬁrm  that  doses
elivered  in  3D  are  signiﬁcantly  higher  than  those  delivered
n  2D  and  that  currently  available  phantoms  are  not  suit-
ble  for  image  quality  control  in  tomosynthesis.  To  integrate
omosynthesis  in  breast  cancer  screening  programs,  we  need
o  develop  suitable  phantoms  and  reading  tables.
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